Advertisement
Singapore markets close in 5 hours 45 minutes

  • Straits Times Index

    3,426.08
    -13.80 (-0.40%)
     

  • Nikkei

    41,051.49
    +137.84 (+0.34%)
     

  • Hang Seng

    17,864.61
    -163.67 (-0.91%)
     

  • FTSE 100

    8,241.26
    +70.14 (+0.86%)
     

  • Bitcoin USD

    55,432.46
    -3,532.50 (-5.99%)
     

  • CMC Crypto 200

    1,166.54
    -94.64 (-7.46%)
     

  • S&P 500

    5,537.02
    +28.01 (+0.51%)
     

  • Dow

    39,308.00
    -23.90 (-0.06%)
     

  • Nasdaq

    18,188.30
    +159.54 (+0.88%)
     

  • Gold

    2,369.40
    0.00 (0.00%)
     

  • Crude Oil

    83.72
    -0.16 (-0.19%)
     

  • 10-Yr Bond

    4.3550
    0.0000 (0.00%)
     

  • FTSE Bursa Malaysia

    1,615.41
    -1.34 (-0.08%)
     

  • Jakarta Composite Index

    7,269.59
    +48.70 (+0.67%)
     

  • PSE Index

    6,549.53
    +42.04 (+0.65%)
     

Former GSK consumer health arm Haleon posts 16.1% jump in quarterly sales

Reuters
Updated ·1-min read
The company logo for Haleon and the trading info is displayed on a screen on the floor of the NYSE in New York

LONDON (Reuters) -Haleon, the former consumer health arm of GSK, on Thursday reported a 16.1% increase in third-quarter reported revenue as it raised prices, and lifted its sales outlook.

The company, which makes Sensodyne toothpaste and Panadol painkillers, said it now expects organic sales growth of 8.0-8.5%, versus its previous forcast of 6-8%.

"We saw accelerated growth in the third quarter in Oral Health, whilst strong comparatives in Vitamins, Minerals and Supplements resulted in category revenue down slightly, overall sales were similar to earlier quarters," Chief Executive Brian McNamara said in a statement.

Haleon said reported operating profit rose 12.2% to 569 million pounds ($647.69 million).

($1 = 0.8785 pounds)

(Reporting by Richa Naidu; Editing by Jan Harvey and Jane Merriman)